Leaflet RESELIGO 10.8mg implant in pre-filled syringe


Indicated for: prostate cancer; breast cancer; endometriosis

Route of administration: implantation

Substance: goserelin (GnRH agonist)

ATC: L02AE03 (Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues)

Goserelin is a medication mainly used in the treatment of prostate cancer in men and breast cancer in women, as well as in some gynecological conditions such as endometriosis. It works by reducing the levels of certain hormones in the body, which helps slow down or stop the growth of cancer cells or abnormal tissue.

The medication is administered as a subcutaneous implant, usually once every few weeks or months, depending on your doctor's instructions. The treatment is closely monitored to assess effectiveness and adjust the dose if necessary.

Side effects may include hot flashes, sweating, decreased libido, mood changes, bone pain, or reactions at the implant site. In some cases, allergic reactions or changes in bone density may occur. Any unusual symptoms should be reported to your doctor.

Goserelin is an effective medication for controlling certain types of cancer and hormonal conditions, but it requires strict medical supervision. Follow the administration schedule and your doctor's instructions to achieve the best results and minimize risks.

General data about RESELIGO 10.8mg

  • Substance: goserelin
  • Date of last drug list: 01-05-2026
  • Commercial code: W62379001
  • Concentration: 10.8mg
  • Pharmaceutical form: implant in pre-filled syringe
  • Quantity: 1
  • Product type: generic
  • Price: 590.68 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: AMW GMBH ARZNEIMITTELWERK WARNGAU - GERMANIA
  • Holder: ALVOGEN IPCO S.AR.L. - LUXEMBURG
  • Number: 8396/2015/01
  • Shelf life: 3 years-after packing for marketing;after the first opening-it is used immediately

Pharmaceutical forms available for goserelin

Concentrations available for goserelin

  • 10.8mg
  • 3.6mg

Compensation lists for RESELIGO 10.8mg Alvogen

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

590.68 RON

590.68 RON

0.00 RON